Dual-Targeting and Armored CAR-T Designs Address the Resistance Problem in Solid Tumors

Chimeric antigen receptor T-cell therapy - known as CAR-T - has established itself as one of the most consequential developments in cancer immunotherapy of the past decade. By engineering a patient's own immune cells to recognize and destroy cancer cells, the approach has achieved responses in patients with blood cancers who had exhausted all other treatment options. But the field is at an inflection point, grappling with the limits of first-generation designs and the demands of extending this success to solid tumors.

An editorial perspective published in Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment," synthesizes recent clinical and translational advances and outlines the engineering roadmap that researchers are pursuing to address the therapy's remaining limitations. Led by Uzma Saqib, with Krishnan Hajela of the School of Life Sciences at Devi Ahilya Vishwavidyalaya as corresponding author, the piece provides a structured assessment of where CAR-T stands and where it is heading.

What CAR-T Has Achieved in Blood Cancers

The clinical record in hematologic malignancies is substantial. CAR-T therapies targeting CD19 have produced durable remissions in B-cell leukemia and lymphoma in patients who had relapsed after multiple prior treatments. Therapies targeting BCMA have shown meaningful responses in multiple myeloma. These results have supported the approval of multiple CAR-T products by the FDA and other regulatory agencies, and have established cellular immunotherapy as a standard treatment option for specific indications.

The CAR-T workflow involves three steps: leukapheresis (collecting the patient's T cells), genetic modification and expansion in the laboratory (introducing the chimeric receptor and growing sufficient numbers of modified cells), and infusion back into the patient after lymphodepletion chemotherapy. The process typically takes several weeks from collection to infusion, which creates challenges for patients with rapidly progressing disease.

Where CAR-T Struggles: The Solid Tumor Problem

The success in blood cancers has not transferred readily to solid tumors, which represent the majority of cancer diagnoses. Three interlocking problems account for most of the failure:

First, antigen selection. Blood cancers often express target antigens - like CD19 - uniformly across tumor cells, making them vulnerable to T cells engineered to recognize that target. Solid tumors are genetically heterogeneous; different cells within the same tumor may express different levels of the target antigen, or lose antigen expression entirely under immune pressure. This "antigen escape" is a primary mechanism by which solid tumors evade CAR-T therapy.

Second, the tumor microenvironment. Solid tumors create a local immunosuppressive milieu - a combination of physical barriers, metabolic conditions hostile to T cells, and suppressive signaling molecules - that limits the ability of CAR-T cells to reach and remain active within the tumor. T cells that arrive at a solid tumor may rapidly become exhausted or dysfunctional.

Third, trafficking. Getting T cells to enter solid tumors at all is challenging. Blood cancers are accessible to circulating immune cells in ways that anatomically enclosed solid tumors - in the brain, pancreas, or ovary - are not.

Next-Generation CAR Designs

The engineering community has responded to these limitations with increasingly sophisticated CAR architectures. The perspective highlights several approaches under active development:

Dual-targeting CARs recognize two different antigens simultaneously, making antigen escape significantly harder - a tumor cell would need to lose both targets to evade the therapy. Switchable or on-off CAR systems allow external control of T-cell activation, potentially reducing on-target/off-tumor toxicity by allowing clinicians to modulate activity after infusion. Armored CARs are engineered to secrete cytokines or other signaling molecules that help overcome the suppressive tumor microenvironment from within the tumor itself.

These designs remain largely in preclinical or early clinical development. The path from engineering innovation to clinical validation is long, and each design introduces new complexities in manufacturing, safety monitoring, and regulatory evaluation.

Safety and Access: Unresolved Challenges

Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the most common serious adverse effects of CAR-T therapy. CRS can range from flu-like symptoms to life-threatening systemic inflammation; neurotoxicity can cause confusion, seizures, and cerebral edema. Both require prompt recognition and treatment in specialized centers.

The perspective highlights equity issues alongside clinical ones. CAR-T therapies carry list prices of several hundred thousand dollars per treatment, and the need for treatment at specialized academic medical centers creates geographic and logistical barriers for patients outside major metropolitan areas. Racial and socioeconomic disparities in access to CAR-T therapy have been documented in the literature, and they limit the real-world impact of a treatment whose clinical efficacy is substantial. Allogeneic or alternative CAR-T platforms - using donor T cells rather than the patient's own, which could be manufactured at scale and used off-the-shelf - are among the approaches being pursued to address these cost and access barriers.